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Abstract
Addiction occurs through repeated abuse of drugs that progressively reduce behavioral control and
cognitive flexibility while increasing limbic negative emotion. Recent discoveries indicate
neuroimmune signaling underlies addiction and co-morbid depression. Low threshold microglia
undergo progressive stages of innate immune activation involving astrocytes and neurons with
repeated drug abuse, stress, and/or cell damage signals. Increased brain NF-κB transcription of
proinflammatory chemokines, cytokines, oxidases, proteases, TLR and other genes create loops
amplifying NF-κB transcription and innate immune target gene expression. Human post-mortem
alcoholic brain has increased NF-κB and NF-κB target gene message, increased microglial
markers and chemokine-MCP1. Polymorphisms of human NF-κB1 and other innate immune
genes contribute to genetic risk for alcoholism. Animal transgenic and genetic studies link NF-κB
innate immune gene expression to alcohol drinking. Human drug addicts show deficits in
behavioral flexibility modeled pre-clinically using reversal learning. Binge alcohol, chronic
cocaine, and lesions link addiction neurobiology to frontal cortex, neuroimmune signaling and loss
of behavioral flexibility. Addiction also involves increasing limbic negative emotion and
depression-like behavior that is reflected in hippocampal neurogenesis. Innate immune activation
parallels loss of neurogenesis and increased depression-like behavior. Protection against loss of
neurogenesis and negative affect by anti-oxidant, anti-inflammatory, anti-depressant, opiate
antagonist and abstinence from ethanol dependence link limbic affect to changes in innate immune
signaling. The hypothesis that innate immune gene induction underlies addiction and affective
disorders creates new targets for therapy.
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Introduction: Severe addiction is the result of loss of behavioral control
and increased limbic drive
Chronic use of alcohol stimulants and/or opiates lead to progressive changes in the brain and
behavior, often leading good, smart and sane people to do bad, stupid and crazy things that
hurt themselves and others. The continued and often escalating horrific, unpleasant, awful
events associated with increasing drug use resulting in addiction are well known. Medical
emergencies due to accidents, drug overdoses, violent desperate, impulsive illegal behavior,
physical injuries criminal justice problems (Li 2008; Gilson 2010) and other negative
consequences associate with drug addiction (Hingson et al. 2009; Mendelson et al. 1986).
Alcohol or opiate dependence was first defined by neurological and physiological
withdrawal symptoms including hyperexcitability, fever, anxiety and feelings of sickness.
However, modern medicine focuses psychological dependence that causes loss of behavioral
control (Kalivas and O'Brien 2008; Koob and Volkow 2010). Addiction can be defined as a
primary, chronic, neurobiological disease, with genetic, psychosocial, and environmental
factors influencing its development and manifestations. It is characterized by behaviors that
include impaired control over drug use, compulsive use, continued use despite harm, and
craving (Ries et al. 2009; Volkow et al. 2011). Substance Dependence, a Psychiatric
diagnosis is defined as “repeated use of alcohol or other drugs despite problems related to
use of the substance (O'Brien 2008). Critical to these medical diagnoses of severe addiction
is the continued use of drugs despite the harm to the individual, family and community due
to the loss of ability to alter behavior in spite of problems. This review will describe changes
in the neurobiology of the brain related to severe addiction.
Addiction involves progressive loss of frontal cortical behavioral control
and increasing limbic temporal lobe negative feelings
The loss of behavioral control that underlies addiction has at least 2 components, decreased
frontal cortical regulation of attention and cognitive flexibility and increased limbic fear-
negative feelings (Fig. 1). The frontal lobes of brain are involved in decision making and
other executive functions such as motivation, planning, goal setting and inhibition of
impulses. Frontal lobe functions also predict future consequences, choose between good and
bad actions (or better and best), override and suppress unacceptable social responses, and
determine similarities and differences between things or events. The frontal lobes also play
an important part in retaining long term emotional memories and adjusting emotions to fit
socially acceptable norms important for individual integration into society. Frontal
behavioral control mechanisms block impulsive mistakes and predict future rewards
(Schoenbaum and Shaham 2008). Loss of these functions is a key element of the
neurobiology of addiction and substance dependence (Fig. 1).
The limbic system supports a variety of functions particularly emotion, fear or elation, needs
and urgency, long term memory, and olfaction. Addiction induced negative affect, mood and
fear are associated with amygdale and hippocampus human temporal lobe structures (Fig.
1). Limbic urgency helps drive impulsive behaviors (Crews and Boettiger 2009). Across
drugs of addition, the progression from abuse to addiction involves increasing drug wanting,
negative emotional urgency and decreasing behavioral control (Jentsch and Taylor 1999;
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Robinson and Berridge 2003). Thus, the neurobiology of addiction involves dysfunctional
frontal cortex behavioral control as well as exaggerated limbic urgency (Fig. 1). This review
will present the hypothesis that innate immune gene induction in frontal cortex blunts
behavioral control, whereas it amplifies limbic negative affect and bad feelings.
Microglia and monocytes sense drug abuse and stress
Neuroimmune signaling contributes to enteric, sensory, endocrine hypothalamic-adrenal
(HPA) responses to external and internal environmental factors. Monocytes and brain
microglia, are sensitive key cells involved in innate immune signaling. Neuroimmune
signaling through microglia and other monocyte-like cells integrates sensory and endocrine
enteric responses with brain. Microglia are unique monocyte-macrophage-like cells that
share multiple stages of activation reflected morphologically and in gene expression
(Hingson et al. 2009; Graeber 2010). Microglia are formed embryonically and migrate to
fetal brain early in development creating a unique self-renewing monocyte-like cell that is
maintained by self-renewal. Microglia and vascular monocyte-macrophages are the primary
innate immune cells in brain (Ransohoff and Cardona 2010). Healthy brain contains
ramified “resting” microglia known to survey brain and regulate synapses (Graeber 2010).
Microglia have a low threshold of activation with initial states secreting signaling molecules,
increasing expression of Major Histocompatibility Complex (MHC) proteins and Toll-like
receptor proteins (TLR), key proteins involved in innate immune amplification.
Morphological activation states show cellular enlargement, increased cell matrix and
adhesion protein expression and progressive induction of other specific genes. Efforts to
establish subtypes of microglia have designated M1 and M2 states as proinflammatory and
trophic respectively, although additional subtypes continually emerge (Colton and Wilcock
2010). Activated enlarged morphology is often associated with secretion of chemokines
regulating cellular movement, particularly to sites of tissue damage, that progress to
proinflammatory-oxidative activation that includes protease secretion. Highly activated
microglia progress to mitosis, proliferation and phagocyte oxidative bursts that oxidize and
engulf waste (Graeber 2010). “Amoeboid” phagocytic rounded macrophage-like cell
morphology is common in neurodegenerative diseases and senescence (Colton and Wilcock
2010). Microglia can also initiate trophic and other signals needed for healing (Crews et al.
2006). Microglia are important components of brain that regulate brain function in complex
ways not fully understood. Emerging studies suggest brain suppress microglial activation
promoting a trophic “resting” state (Liu et al.). Stress, ethanol, other addictive drugs as well
as sensory and hormonal signals activate monocytes and microglia. Cycles of stimuli lead to
microglial adaptive conditioning (Shpargel et al. 2008). Interestingly, microglial dysfunction
has been discovered to contribute to obsessive-compulsive behaviors (Greer and Capecchi
2002), consistent with microglia contributing to the neurobiology of addiction. Thus,
microglia are sensitive to addictive drugs and stress, that lead to progressive adaptation that
could alter neurobiology and behavior through innate immune gene induction.
Stress and drug abuse promote addiction and NF-κB Transcription of
Innate Immune Genes
Stress, ethanol, other addictive drugs, as well as sensory and hormonal signals, activate an
oxidation sensitive transcription factor, NF-κB (nuclear factor kappa-light-chain-enhancer
of activated B cells), that is highly expressed in monocytes and microglia. Monocytes and
microglia express high levels of the transcription factor NF-κB as well as low levels of
innate immune genes under normal conditions. Although NF-κB is found in most cells, it is
the key transcription factor involved in induction of innate immune genes in microglia and
other monocyte-like cells. Stimuli such as stress, cytokines, oxidative free radicals,
ultraviolet irradiation, bacterial or viral antigens, and many other signaling molecules
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increase NF-κB-DNA binding and transcription of many genes particularly chemokines,
cytokines, oxidases and proteases (Fig. 2). We find that ethanol increases NF-κB–DNA
binding in brain in-vivo (Crews et al. 2006) or in-vitro in hippocampal-entorhinal cortex
(HEC) brain slice cultures (Zou and Crews 2006). Our studies and others indicate that
ethanol increases transcription of NF-κB target genes including the chemokine MCP-1
(CCL2), the proinflammatory cytokines, TNFα, IL-1β, and IL6, the proinflammatory
oxidases, iNOS (Zou and Crews 2010), COX (Knapp and Crews 1999), NOX (Qin et al.
2008) and proteases TACE and tPA (Zou and Crews 2010) (Fig. 2). Similarly stress
increases brain NF-κB activation (Madrigal et al. 2001), cytokines, prostaglandin E2 and
COX-2 levels (Madrigal et al. 2003) in part due to reversal of acute glucocorticoid anti-
inflammatory responses to pro-inflammatory NF-κB activation in frontal cortex (Munhoz et
al. 2010). Stress and drug abuse cycles promote addiction and elevate glucocorticoids
(Armario 2010), likely contributing to activation of brain NF-κB transcription of innate
immune genes. Methamphetamine shows similar persistent innate immune activation to
ethanol in mice and humans (Loftis et al. 2010). Thus, the synergy of stress-drug abuse
cycles leading to progressive loss of behavioral control and addiction are consistent with
persistent, progressive brain innate immune gene induction.
Loops amplify NF-κB innate immune gene induction by paracrine and
autocrine processes
Activation of the NF-κB spreads through positive loops (Fig. 2) increasing activation within
and across glia and neurons (Zou and Crews 2010). Autocrine signaling involves secretion
of signaling molecules that act on the same cells receptors to amplify activation of that cell,
whereas paracrine signaling involves release of signals that activate cells nearby spreading
the signal across cells. For example, reactive oxygen species (ROS) can increase NF-κB
transcription of TNFα and TACE, the TNFα activating protease, as well as the TNFR1
receptor. Released TNFα stimulates NF-κB transcription through TNFR1 amplifying the
signal in that cell and adjacent cells promoting TNFα induction (Fig. 2). Stress and drugs
acutely signal through brain NF-κB. For example, restraint stress in rats induces brain NF-
κB target genes TACE and TNFα mRNA within 30 minutes, and free mature brain TNFα
within 1 hour (Madrigal et al. 2002). Similarly an acute dose of ethanol activates NF-κB in
brain within 30 minutes (Ward et al. 1996). Although NF-κB is expressed in most cells, in
brain NF-κB is transcriptionally active primarily in glia (Mao et al. 2009), although,
confusion regarding neuronal NF-κB is commonly found in the literature (Massa et al.
2006). Activation of NF-κB acutely leads to paracrine and autocrine amplification during
repeated drug abuse and/or stressful events that create loops of NF-κB activation amplifying
innate immune gene induction (Fig. 2). The loops of NF-κB activation lead to persistent
increases in oxidative free radicals from oxidases, increased TLR expression with increased
formation of endogenous TRL agonists, and chemokine-cytokine receptor upregulation (Qin
et al. 2008; Zou and Crews 2010). Ethanol and stress activate microglia to secrete NF-κB
target genes leading to mild activated morphology with repeated cycles progressively
increasing innate immune gene induction. Maximally activated phagocytic oxidative burst
macrophage-like microglial activation occurs with severe neurodegeneration, but is rare in
addiction without severe degeneration (He and Crews 2008; Qin et al. 2008). These studies
indicate that repeated drug abuse and stress lead to loops of NF-κB transcription of innate
immune genes that mimic the progressive and persistent changes in behavior associated with
the transition from drug experimentation to addiction.
Astrocytes and microglia are activated in addiction
A number of studies suggest astrocytes and microglia are activated in addiction. Using both
in vitro and in vivo models through a series of elegant studies Guerri's laboratory has clearly
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established that chronic ethanol treatment induces astroglial activation and astrogliosis in
brain as indicated by marked upregulation of GFAP immunoreactivity within hypertrophic
astrocytes, (Wilhelmsson et al. 2006; Chvatal et al. 2007; Gomez-Pinedo et al. 2008). TLR
are pattern recognition receptors that activate NF-κB transcription. TLR and interleukin-1
receptors are expressed on microglia and other cells during innate immune activation
contributing to amplification of signaling. Recently TLR4 was discovered to contribute to
persistent innate immune gene induction and neurodegeneration by ethanol (Alfonso-
Loeches et al. 2010). Guerri's studies indicate that chronic ethanol upregulation and
activation of TLR4-MyD88-glial NF-κB signaling contributes to alcohol induced
neurodegeneration. Acute alcohol activates TLR4 signaling to NF-κB as well as increasing
expression of TLR4 (Alfonso-Loeches et al. 2010). These studies are consistent with ethanol
induction of innate immune genes altering behavior and causing neurodegeneration related
to addiction. Indomethacin, an anti-inflammatory drug, reduces chronic ethanol induction of
brain innate immune genes, particularly in astrocytes, as well as neuronal markers of cell
death and addiction-like behavioral dysfunction (Pascual et al. 2007) consistent with innate
immune gene induction driving the neurobiology of addiction. Innate immune activation
from oxidized phospholipids (Yang et al. 2010), and/or release of damage associated
molecular pattern (DAMP) danger sensing molecules, such as high-mobility group box 1
(HMGB1) (Garg et al. 2010), that activate TLR and other signals are likely contributors to
innate immune gene induction (Huang et al. 2010)(Fig. 2). Although loops of NF-κB
activation are best established in models of alcoholism, all addictive drugs activate NF-κB
transcription with the development of addiction (Russo et al. 2009; Loftis et al. 2010). These
studies support innate immune gene induction in glia as important contributors to the
neurobiology of addiction.
Innate immune molecules mimic stress and drug induced addiction-like
behavior
Anxiety and the bad feelings of negative affect are associated with increased drug craving as
a key component of addiction (Breese et al. 2005; Koob and Volkow 2010). Breese'
laboratory models addiction with repeated cycles of ethanol consumption and/or stress that
progressively amplify anxiety and negative affect consistent with the cycles of stress and
drug abuse known to promote addiction. Interestingly, brain injections of innate immune
inducing molecules, e.g. the chemokine MCP-1, the cytokine TNFα, or the TLR4 agonist,
lipopolysaccaride an innate immune inducer, progressively increase addiction-like anxiety
substituting for an episode of stress or drug abuse (Breese et al. 2008). Cycles of stress and/
or drug abuse cause progressive addiction-like anxiety and are known to induce innate
immune genes in brain. The discovery that innate immune molecules injected into brain
substitute for stress and/or drug abuse cycles promoting addiction-like anxiety, supports the
role innate immune genes in driving the neurocircuitry and neurobiology that result in
addiction-like behavior.
Naltrexone, an opiate antagonist used to treat addiction, blunts innate
immune induction
Opiates are known to be addicting drugs and have endogenous opiate receptors that
contribute to the neurobiology of addiction (Koob and Volkow 2010). Opiate antagonists are
used to treat both alcohol and opiate addiction. Interestingly, opiate antagonists block innate
immune gene induction through a different novel mechanism that might contribute to the
reversal of addiction-like behavior. LPS, endotoxin, induces large innate immune responses
that are blocked by opiate antagonists (Liu et al. 2000) and protect dopamine neurons
through inhibition of microglial innate immune activation and reduced NOX formation of
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ROS (Liu et al. 2000; Qin et al. 2005), independent of their opiate antagonist actions. Other
studies find opiate antagonists block TLR4 activation of innate immune transcription, a site
of action in innate immune loops (Fig. 2) (Gerald Frank 2011; Hutchinson 2011). Thus,
opiate antagonist addiction therapy may be related to inhibition of innate immune responses.
Innate immune genes are increased in addicted brain
Insight into the neurobiology of addiction can be gained from studies of post-mortem human
brain. We found monocyte chemoattractant protein 1 (MCP-1, CCL2), a key innate immune
chemokine, increased several fold in multiple regions of post-mortem alcoholic brain
compared to age matched moderate drinking controls (Fig. 3) (He and Crews 2008). MCP-1
protein levels from alcoholic and control human brains indicated increased MCP-1 in ventral
tegmental area (VTA), substantia nigra (SN), hippocampus and amygdala of alcoholic
brains. We also found increased levels of microglial markers across alcoholic brain (He and
Crews 2008). Chronic alcohol treatment of mice causes a similar persistent increase in brain
MCP-1 (Fig. 3) (Qin et al. 2008). Interestingly, ethanol treatment of rat hippocampal brain
slice cultures also increase MCP-1 and other innate immune genes (Fig. 3) (Zou and Crews
2010). These studies indicate that ethanol induces MCP-1 in rats and mice creating
neurobiological changes found in human addicted brain (Fig. 3). Similarly, human
methamphetamine addicts and mice treated with methamphetamine show persistent
increases in innate immune proteins (Loftis et al. 2010). Increased protein levels are also
reflected by increased mRNA. Gene arrays following mRNA expression in post-mortem
human alcoholic brain find increased NF-κB and target gene expression. Okvist (2007)
found chronic alcoholic brain to contain increased NF-κB nuclear binding p50 subunits with
479 NF-κB target genes upregulated in the frontal cortex. Another post-mortem alcoholic
human gene expression analysis (Liu et al. 2006) found increases in innate immune cell
adhesion and extracellular membrane (ECM) components. Thus, studies of post-mortem
human alcoholic brain are consistent with increased innate immune gene expression in
addicted brain.
Polymorphisms of innate immune genes and genetic risk of addiction
Genetics contribute to risk of addiction with alcoholism being the most studied and
experimentally established addiction with a significant genetic risk. Genes explain about
50% of the risk of alcohol addiction (Schuckit 2009). Interestingly, polymorphisms of
Cyp2E1, an enzyme that metabolizes ethanol is associated with risk for alcoholism (Webb et
al. 2010). In vivo, Cyp2E1 is highly expressed in monocyte-like cells where ethanol is
immediately sensed through osmotic and Cyp2E1 metabolism. Cyp2E1 metabolism of
ethanol increases ROS that activate proinflammatory NF-κB responses (Cao et al. 2005)
(Fig. 2). Other human studies have found a direct link of NF-κB p50 to alcohol dependence
(Flatscher-Bader et al. 2005; Okvist et al. 2007;Taylor et al. 2008). Polymorphisms in the
precursor gene (NF-κB 1) of the NF-κB p50 subunit associate with risk for alcoholism
(Taylor et al. 2008). Alleles of TNFα that increase expression have been linked to
alcoholism and alcoholic liver disease (Pastor et al. 2000; Powell et al. 2000; Pastor et al.
2005). Alleles of IL-10 have also been linked to alcoholism (Pastor et al. 2000).
Interestingly, in both cases alleles associated with alcoholism increase pro-inflammatory
responses, e.g. alleles associated with alcoholism increase pro-inflammatory cytokine TNFα
and decrease anti-inflammatory IL-10 secretion. Similarly polymorphisms, to the
Interleukin-1 receptor antagonist and multiple other alleles of the IL-1 gene complex are
associated with risk for alcoholism (Saiz et al. 2009). Thus, gene polymorphisms that alter
innate immune NF-κB and NF-κB target gene expression are associated with genetic risk
for human alcoholism consistent with increased brain innate immune gene expression
contributing to the neurobiology of addiction.
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Innate immune gene expression in brain changes behavior
Innate immune gene expression is known to alter behavior. The most serious side effect of
treatment of cancer patients with proinflammatory interferon and interleukin is severe
depression that must be treated with antidepressants. Multiple other studies have linked
negative affect and depression to innate immune activation (Kelley 2011). Bacterial
endotoxin (LPS) an effective inducer of innate immune genes causes sickness behavior and
negative affect across multiple species. In rodents, models of depression-like behavior are
linked to innate immune activation and in healthy humans LPS infusions reduce reward
responses and increase depressed mood (Eisenberger et al. 2010). Increased negative affect
is an important component of the neurobiology of addiction (Koob and Volkow 2010).
Drug consumption is also linked to innate immune gene expression. Addictionlike drinking
behavior in rats and mice associates with increased NF-κB, its regulatory proteins and innate
immune genes (Mulligan et al. 2006). Interestingly, microglobulin (β2M) an NF-κB target
gene involved in microglial MHC immune signaling (Pahl 1999) shows the largest increase
in high alcohol preferring brain transcriptomes (Mulligan et al. 2006). Innate immune gene
induction in multiple mouse studies finds induction suppression through transgenic knock
outs associates with increased drinking or decreased drinking respectively across strains of
mice. These studies further support the role of these genes in regulating excessive addiction
like drug consumption (Blednov et al. 2005; Blednov 2010). A single injection of LPS is
able to produce a long-lasting increase in alcohol consumption (Blednov 2011) that
corresponds to persistent increases in brain innate immune gene expression (Qin et al. 2007).
These findings are consistent with innate immune gene expression driving addiction like
behavior, both excessive consumption and the negative-affect, anxiety and depression-like
behaviors of addiction.
Innate immune genes increase negative affect and reduce neurogenesis.
creating the neurobiology of addiction
Emotion or affect have an impact on health with positive affect or happiness associating
with health and negative affect, bad feeling with illness. Psychiatric affective disorders
cover a range of negative affect elements including anger, anxiety, melancholia, depression,
major depressive disorder and substance use disorder. Drug addiction cues include a visceral
emotional “gut” reaction, often one of uneasiness until the habit is satisfied. A variety of
studies suggest that the extended amygdale, a neuroanatomic circuit including the amygdale,
hippocampus, bed nucleus of the stria terminalis and the nucleus accumbens integrate brain
arousal–stress systems producing negative emotional states that promote the development of
addiction (Koob and Volkow 2010). Mood and negative affect are reflected in the co-
morbidity of addiction and depression. About half of individuals with a lifetime history of
alcoholism also have depression (Miller et al. 1996; Schuckit et al. 1997) and reversal of
depression and alcohol dependence are linked (Mueller et al. 1994; Greenfield et al. 1998).
Progressive drug-induced negative affect and depression-like behaviors are important
components of addiction (Koob and Volkow 2010). The overlapping findings of increased
innate immune gene expression in addiction and depression are consistent with a common
molecular mechanism of addiction induced depression and endogenous depression.
A significant body of evidence supports the hypothesis that innate immune gene induction in
brain causes negative affect and depression-like behavior (Raison et al. 2009). Patients with
major depression have increased blood proinflammatory markers and antidepressant therapy
is associated with decreases in markers. In addition to increased innate immune gene
expression, human depression involves structural changes in hippocampus with multiple
studies finding hippocampal volume is decreased in patients with depression (Videbech and
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Ravnkilde 2004). Other studies have associated loss of hippocampal neurogenesis, the
formation of new neurons, with depression and hippocampal shrinkage. Interestingly,
antidepressants increase hippocampal neurogenesis in models of depression and increase
humans hippocampal volume during reversal of depression (Dranovsky and Hen 2006).
Stress, multiple addictive drugs, innate immune genes and other factors that precipitate
depression, reduce hippocampal neurogenesis (Tanapat et al. 2001; Malberg and Duman
2003; Gregus et al. 2005). Factors that reduce neurogenesis increase depression-like
behavior (Johnson et al. 2006). Activation of NF-κB is necessary for stress induced
inhibition of neurogenesis and induction of depression-like behavior (Koo and Duman 2008)
as well as social defeat models of depression (Christoffel et al. 2011). Further,
antidepressant efficacy in rodent behavioral models requires hippocampal neurogenesis
(Santarelli et al. 2003). In animal studies, endotoxin induced increases in innate immune
genes reduce neurogenesis and increase depression-like behavior (Kelley 2011). TLRs are
necessary components of both ethanol neurotoxicity (Alfonso-Loeches et al. 2010) and
innate immune induced depressive behavior and reduction of neurogenesis (Kelley 2011).
TLR, glutamate hyperexcitability and endogenous TLR agonists lead to persistent increases
in brain hyperexcitability (Maroso et al. 2010). We have found that chronic ethanol
increases brain innate immune genes, reduces brain neurogenesis and increases depression-
like behavior (Stevenson et al. 2009) (Fig. 4.) Ethanol induced loss of neurogenesis
paralleled the onset of depression-like behavior with both reversed by anti-depressant
treatment (Stevenson et al. 2009). Similarly stress induced IL-1β reduces neurogenesis
causing depression like behavior (Koo and Duman 2008). Thus, neurogenesis reflects mood,
with reduced neurogenesis associated with innate immune gene induction, drug induced
negative affect and depression-like behavior. Interestingly, recovery from alcoholism is
associated with improved mood and cognition, human brain enlargement and increased
neurogenesis (Crews and Nixon 2009). Overall findings suggest adult hippocampal stem
cells and neurogenesis provide an index of mood and negative affect that allow molecular
studies on regulation of mood, both negative and positive (Crews and Nixon 2003; Koo et
al. 2011) (Fig.4). These findings are consistent with drug induced depression sharing
common mechanisms with endogenous depression as well as the negative affect of
substance use disorder, e. g. addiction.
Frontal cortical hyperexcitability, a key element of the neurobiology of
addiction
The frontal cortex is involved in attention, rule setting, decisions and behavioral control. It
connects to multiple brain regions through excitatory glutamatergic neurons. Reciprocal
connections to thalamus and limbic regions involve focal excitation that is disrupted by
innate immune gene induction. In astrocytes, activation of NF-κB increasing expression of
proinflammatory innate immune genes (Zou and Crews 2006; Pascual et al. 2007; Zou and
Crews 2010) and reduces astrocyte glutamate transport (Zou and Crews 2005) causing an
increase in extracellular glutamate increasing neuron excitiation and excitotoxicity (Zou and
Crews 2006). Innate immune induced hyperexcitability due to loss of cortical glutamate
transporters inactivates the frontal lobes contributing to the neurobiology of addiction
(Crews et al. 2006). Other studies have indicated genetic factors linked to a hyperglutamate
state to alcoholism (Spinagel, 2005) and ethanol induced NF-κB activation to increased
extracellular glutamate (Ward et al. 2009). Innate immune gene induction causes
hyperexcitability in the spinal cord related to neuropathic pain (Graeber 2010) and in the
hippocampus related to seizures (Maroso et al. 2010). Hyperexcitability in the frontal cortex
results in loss of cognitive flexibility creating addiction-like behavior (Gruber 2010).
Kalivas' laboratory in elegant studies have established that cocaine and stimulant addiction
are related to hyperglutamate states due to alterations in the cortical glutamate transporters,
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(Reissner and Kalivas 2010). These studies and others have suggested that anti-oxidants and
other drugs that block innate immune gene cascades may provide new therapies for
addiction.
Behavioral inflexibility and bad decisions due to innate immune gene
induction
Frontal cortical dysfunction is often investigated using reversal learning tasks. In reversal
learning, expected outcomes are wrong requiring flexible behavior in response to outcomes
that do not match those predicted by the preceding cues (Stalnaker et al. 2009). Reversal
learning tasks in behavioral studies mimic the inability of drug addicted individuals to learn
new healthy behaviors, when alcohol and other drugs have established strong associations.
A frontal cortical signal is needed to indicate the value of decisions and is needed when new
learning and/or behavior is necessary. We found that models of binge drinking induce
persistent deficits in reversal learning in rats (Obernier et al. 2002) and in adult mice
following a model of adolescent binge drinking (Coleman 2010). Other studies have found
rats with previous experience either with self-administration of cocaine or with passive
cocaine injections, are abnormally slow to learn reversals, even though they learn initial
contingencies at a normal rate (Schoenbaum et al. 2004; Calu et al. 2007). Lesions of the
frontal cortex cause reversal learning deficits in tasks similar to chronic drug abuse induced
deficits (Schoenbaum et al. 2006). Studies of both human cocaine and alcohol addicts have
found dysfunctional decision making in tasks involving delaying reward for more value and
reversal learning tasks that probe cognitive flexibility and frontal lobe function (Bechara et
al. 2002). The persistence of addiction, a chronic relapsing disorder, compares with the
persistence in innate immune gene induction (Qin et al. 2007; Qin et al. 2008) and loss of
behavioral flexibility.
Adolescence, a key period of risk for frontal cortical damage
Adolescence is an important developmental period when drug experimentation increases and
behavioral control mechanisms mature. The frontal cortex develops during adolescence in
parallel with the development of behavioral control (Ernst et al. 2009). The adolescent
frontal cortex is uniquely sensitive to binge drinking neurotoxicity (Crews et al. 2000) and
adolescent hippocampus uniquely sensitive to alcohol inhibition hippocampal of
neurogenesis (Crews et al. 2006). Loss of frontal cortical function causes perseveration and
repetition of previously learned behaviors due to failure to associate new information, e.g.
negative consequences, into decision making. Models of adolescent binge drinking result in
persistent reversal learning deficits (Coleman 2010) and persistent increases in
proinflammatory innate immune gene expression and markers of neurodegeneration
(Pascual et al. 2007). Anti-infammatory drugs protect against adolescent binge drinking
brain damage models (Pascual et al. 2007) Initiation of drug experimentation during
adolescence when frontal cortical behavioral control circuitry is developing increases
vulnerability for life-long addiction (Crews et al. 2007). These studies suggest anti-
inflammatory therapies may have value in reducing drug induced changes in neurobiology
that contribute to addiction.
Summary
The neurobiology of addiction develops over a course of repeated drug abuse and/or stress.
Changes in neurobiology underline altered mood and cognition related to increased limbic
negative affect and loss of frontal cortical behavioral control. Drug abuse, stress and other
factors increase NF-κB transcription of multiple proinflammatory genes that spread across
brain cell types further amplifying of NF-κB transcription through loops involving
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cytokines, chemokines, oxidases and proteases. Evidence supports the spread and
persistence of brain innate immune gene induction as creating the neurobiology of addiction.
Human studies of genetic risk for alcoholism and post-mortem brain support the role of
innate immune genes in addiction. Animal behavior studies indicate increasing drug
consumption and mounting negative affect and depression-like behavior are due to innate
immune gene induction. Further, frontal cortical hyperexcitability, behavioral flexibility and
loss of behavioral control can all be linked to innate immune genes. Together these finding
suggest the neurobiology of addiction is due to innate immune gene altered signaling
inducing the behaviors that define addiction. Therapies that blunt brain innate immune gene
induction may represent new and novel approaches to preventing and/or reversing addiction.
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Abbreviations
AP1 Activator protein 1
CYP2E1 Cytochrome P450 2E1
DAMPs Damage-associated molecular pattern
ECM Extra cellular matix
EtOH Ethanol
HMGB1 high mobility group box 1
IL-1β Interleukin-1 beta
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MCP-1 Monocyte chemoattractant protein-1
NOX Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases
gp91 NADPH oxidase flavocytochrome b components
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
TLR Toll-Like receptor
TNFα Tissue necrosis factor-alpha
TACE TNFα converting enzyme
tPA Tissue Plasminogen Activator
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Figure 1. Neuroanatomical components of the neurobiology of addiction
A simplified schematic diagram of the human brain frontal-cortical and limbic circuitry that
contribute to addiction. Shown are internal structures highlighted with projections indicated
by arrows with the structure color. Frontal cortical brain regions select attention, monitor the
environment and planning by assessing information and predicting outcomes (Schoenbaum
et al. 2006; Schoenbaum and Shaham 2008). Limbic regions including the amygdala (AMG)
and entorhinal cortex (ENT) also project to VS, from the temporal lobe. The harmful
behaviors of severe alcohol, opiate and stimulant drug dependence involve changes in
frontal lobes leading to loss of attention, poor decision making, and decreased cognitive
flexibility as well as increased temporal lobe anxiety-negative affect urgency that promote
the progressive loss of behavioral control over drug use. Frontal cortex regulation of limbic
structures and communication with sensory thalamic input is glutamatergic. Glutamatergic
hyperexcitability, due to disrupted innate immune gene induction (Zou and Crews 2005;
Crews et al. 2006), inactivates frontal cortical responses (Gruber 2010). Temporal lobe
limbic signaling involves GABAergic and peptidergic projection neurons that show
increased bad feelings due to activation of innate immune genes in hippocampus and
amygdale and loss of frontal cortical control increasing urgency-negative affect. Thus,
innate immune gene induction in frontal and temporal lobes of brain disrupt neurocircuitry
and signaling consistent with addiction.
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Figure 2. Loops of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)
activation of transcription increases chemokines-cytokines, oxidases and proteases
NF-κB is a key transcription factor involved in induction of innate immune genes (Ghosh
and Hayden 2008). Stimuli such as stress, drugs, peptides chemokines, cytokines, reactive
oxygen species, ultraviolet irradiation, bacteria, viruses, trauma and other factors increase
NF-κB-DNA binding and transcription (Fig. 2). Reactive oxygen species (ROS) from
oxidases such as NADPH-oxidase (NOX) or ethanol metabolism by Cyp2E1 increase NF-
κB transcription of NOX2phox (gp91) a key NOX catalytic subunit (Cao et al. 2005) that
produces ROS (Qin et al. 2008). Cytokines and chemokines, such as TNFα, IL1β, IL6 and
MCP-1, as well as their receptors (TNFR in figure) are induced creating another
amplification loop. Toll Like-Receptors (TLR) are increased by ethanol (Alfonso-Loeches et
al. 2010) as are other damage-associated molecular pattern (DAMP) receptors and there
agonists creating positive activation loops (Garg et al. 2010). TLR and HMGB1 create
another activation-amplification loop. Persistent and repeated activation occurs through
positive cycles of activation (+ loops). These loops spread innate immune signaling through
paracrine and autocrine mechanisms across brain altering neurocircuitry and neurobiology.
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Figure 3. Increased CCL2 in post-mortem human alcoholic brain, chronic alcohol treated mouse
brain and ethanol treatment of rat hippocampal-entorhinal cortex (HEC) brain slices cultures
Left-MCP-1 protein levels from human brain homogenate contain increased MCP-1 in
ventral tegmental area, substantia nigra, hippocampus and amygdala. (He and Crews 2008).
Middle: Mouse Brain MCP-1 is increased by chronic ethanol treatment. Mice (C57Bl/6)
were treated with10 daily doses of ethanol (5 gm/kg. i.g., (Qin et al. 2008). Shown are brain
levels of MCP-1 in mice 8 days after chronic ethanol treatment Right: Rat Hippocampal
HEC brain-slice cultures treated with ethanol for 4 days. Shown are MCP-1 and tPA. (Zou
and Crews 2010). These studies indicate ethanol induces the innate immune chemokine
MCP-1 in mouse and rat brain and suggest alcoholics induce MCP-1 through alcohol
drinking. Elevated MCP-1 in post-mortem human alcoholic brain is consistent with ethanol
activation of innate immune genes contributing to alcoholism.
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Figure 4. Chronic alcohol self-administration induces depression-like behavior and inhibits
hippocampal neurogenesis: reversal by the antidepressant Desipramine
C57BL/6J mice self-administered ethanol (10% v/v) or water for 28 days. Forced Swim Test
(FST) immobility is an index of depression-like behavior. The increase in FST immobility
reflects chronic alcohol induced depression-negative affect. Treatment with the
antidepressant, Desipramine, reverses depression-like behavior, e.g. decreases immobility.
(Middle) Ethanol decreases doublecortin (DCX+IR), a marker of neurogenesis. Desipramine
treatment reverses ethanol DCX-neurogenesis. (Right) Pictures of DCX stain in water-
control animals and alcohol animals. These findings are consistent with drug induced
negative affect reflected in loss of neurogenesis and depression-like behavior. This figure is
adapted from Stevenson (Stevenson et al. 2009).
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